The film “Living with GIST” from the Swiss GIST group wins a Silver Edi. On 3rd November 2011, the twelfth Edi film prize for the best advertising, industrial and corporate films in Switzerland was awarded. The film won in the “Corporate: Internal Communication Training” section.
This film shows the way from a correct diagnosis to treatment and dealing with the rare cancer GIST through different patient stories. It is focussing on the global networking of patients and physicians and the collaboration of various medical disciplines and research. The focus of all these efforts is the patient. Three patients are talking about their fate, their lives and their cancer journey. The trailer of the film with English subtitles is available on YouTube.
Since its founding in 2004, the Liddy Shriver Sarcoma Initiative has had an international focus. Back then, we started by publishing the “Sarcoma Facts” in five languages when we launched our website. Today we list them in twenty-three languages. We also employed the slogan “Sarcoma Knows No Borders,” because it is a disease that can be found anywhere in the body and everywhere in the world. We want our efforts to include all those affected by sarcoma and everyone who works to help those with sarcoma. Read more about our efforts and their international focus.
SPAEN is delighted to provide a comprehensive report of the ASCO 2011 medical highlights in GIST and Sarcomas from Dr Axel Le Cesne, Gustave Roussy Institute, Villejuif (France). This ASCO 2011 meeting was marked by the dedication of five full sessions (including plenary and parallel) to GIST and Sarcomas, a massive program fully vindicated by the many exciting advances in research reported on GISTS and Soft Tissue Sarcomas.
ASCO 2011 News: Ridaforolimus Achieved Primary Endpoint of Improved Progression-Free Survival (PFS) in Metastatic Soft-tissue or Bone Sarcomas
Merck/MSD and ARIAD announced on the 6th of June 2011 the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral Ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favourable response to chemotherapy. In this patient population, Ridaforolimus improved progression-free survival (PFS) compared to placebo, the primary endpoint of the study. The complete study results were presented during the 2011 ASCO meeting in Chicago.
ASCO 2011 News: 36 months adjuvant Imatinib-treatment for high-risk-GISTs improves recurrence-free survival (RFS) and even overall survival (OS)
Europe/Chicago, Sunday 5th of June 2011 (mw): For some weeks the international “GIST Community” has anticipated important news at the ASCO-Conference, running from 4 - 8 June 2011 in the Chicago/USA. Over 30.000 healthcare professionals, patient advocates and pharma representatives from all over the world meet annually for this important educational and scientific conference on cancer treatment.
GIST-patients and their doctors have been expecting new data from studies on adjuvant treatment with Imatinib (Glivec® in Europe/Australia, Gleevec™ in the USA) in GIST (Gastrointestinal Stromal Tumour).
The Adult Sarcoma Medical Oncology Clinic at the Instituto Nazionale Dei Tumori (INT) in Milan is now enrolling chordoma patients for two molecularly informed clinical trials. Unlike traditional clinical trials that accept all patients with a given disease, molecularly informed cancer clinical trials only accept patients in whose tumors the drug target is present. This increases the likelihood of success of the clinical trial and prevents patients whose tumors are unlikely to respond from being subjected to chemotherapy.
On 13-15 May 2011, the 9th International Conference for Organisations representing GIST and CML patients took place in Amsterdam. The conference provided patient advocate leaders with an opportunity for 3 days of learning, companionship and the chance to share experiences across borders. The conference welcomed 137 patient representatives (96 CML; 41 GIST) from 48 countries in Europe, North America, Asia, Australia, Africa, Middle East and Latin America.